Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

Lee HC, Shah JJ, Feng L, Manasanch EE, Lu R, Morphey A, Crumpton B, Patel KK, Wang ML, Alexanian R, Thomas SK, Weber DM, Orlowski RZ.

Blood Cancer J. 2019 Oct 1;9(10):80. doi: 10.1038/s41408-019-0240-6. No abstract available.

2.

A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

Lee HC, Shah JJ, Feng L, Morphey A, Johnson RJ, Wesson ET, Wang ML, Alexanian R, Thomas SK, Orlowski RZ, Weber DM.

Am J Hematol. 2019 Dec;94(12):E319-E322. doi: 10.1002/ajh.25633. Epub 2019 Oct 4. No abstract available.

PMID:
31489991
3.

Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma.

Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Olsem J, Crumpton B, Morphey A, Berkova Z, Feng L, Orlowski RZ.

Haematologica. 2019 Aug 14. pii: haematol.2019.225375. doi: 10.3324/haematol.2019.225375. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center